A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-II)

Trial Profile

A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-II)

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Oct 2015

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms TURQUOISE-II
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 01 Oct 2015 Results will be presented at the The Liver Meeting 2015 - the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), according to an AbbVie media release.
    • 12 May 2015 Data from this trial will be presented at Digestive Disease Week 2015, according to an AbbVie media release.
    • 08 May 2014 AbbVie filed an MAA to the EU which included data from the SAPPHIRE I, SAPPHIRE II, PEARL II, PEARL III, PEARL IV and TURQUOISE II trials, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top